The culture shock is real, but survivable

You finish a PhD or postdoc with a deep, hard-won expertise in a narrow slice of bioscience. You know your assay, your cell line, your statistical method. Then you start in a diagnostics company, a biotech scale-up or a contract research organisation, and within a fortnight you realise that nobody is particularly interested in your thesis chapter. They are interested in whether the work can be delivered on time, to a defined specification, and at a cost the business can justify.

That shift catches people out. It is not that industry science is less rigorous — in regulated diagnostics it is often far more rigorous — but the questions change. In academia, the driving question is "what is true?" In industry, it is "what is true, and can we do it reproducibly, on budget, in a way that satisfies a customer, a regulator or an investor?" Both are worthwhile. They simply require different habits.

Project planning when the deadline has money attached

Academic timelines are elastic. A project drifts six months, a paper goes to a second journal, and life continues. Industry timelines are usually tied to a funding milestone, a regulatory submission window, a product launch or a client contract. Slippage has a cost, and it is often someone else's cost.

Practically, this means you will be asked to plan in a way that feels unfamiliar at first. Expect to work with stage-gate or phase-gate reviews, where progress is formally assessed before the next tranche of resource is released. Expect to break work into tasks with named owners, dependencies and durations, whether that sits in a spreadsheet or a proper scheduling tool. Expect to be asked, regularly, "what is the risk here, and what is your mitigation?"

Useful habits to build early:

• Estimate in ranges, not single numbers, and state your assumptions openly.
• Flag slippage the moment you see it, not at the deadline. Bad news does not improve with age.
• Keep a decision log. Months later, "why did we choose this buffer?" is a question someone will ask.
• Distinguish critical-path work from nice-to-have work, and protect the former ruthlessly.

Commercial awareness is a skill you can learn

Commercial awareness sounds vague, but in practice it is a set of concrete questions. Who pays for this work? What does the customer or regulator actually need to see? What is the cost per sample, per run, per patient? If we halve the turnaround time, does that create value, or just cost?

In clinical diagnostics, this matters enormously. A test that performs beautifully in a research lab but cannot be run at scale on the analysers available in a district general hospital is a commercial dead end. A biomarker with superb sensitivity but no reimbursement pathway will struggle to reach patients. Understanding the whole chain — from sample collection and stability through to reporting, accreditation and clinical utility — will make you far more useful than assay skill alone.

Soak up the language of the business. Learn what a validation versus a verification study means in your regulatory context. Understand the difference between research-use-only and in vitro diagnostic claims, and why that distinction shapes everything from labelling to lot release. Ask your commercial colleagues what keeps them awake. They will tell you, and you will be better at your job for knowing.

Teamwork, handovers and the matrix

Academic science rewards individual ownership. Industry science runs on handovers. Your carefully optimised protocol needs to be transferred to a colleague in another site, run by a technician you have never met, on equipment that is nominally equivalent but subtly different. If it only works in your hands, it is not finished.

You will likely work in a matrix: reporting to a line manager while delivering to a project lead, with input from quality, regulatory, manufacturing and commercial stakeholders. That means writing things down clearly, running meetings with agendas, and being comfortable when decisions are made by people who are not the deepest technical expert in the room.

Documentation is not bureaucracy for its own sake. A well-written standard operating procedure, a clean electronic laboratory notebook entry, a properly completed deviation report — these are the mechanisms by which a result becomes trustworthy and reproducible. Treat them as part of the science, because in a regulated environment they are.

Quality systems, regulation and the long memory of documents

UK laboratory science operates within a dense framework: ISO 15189 for medical laboratories, ISO 13485 for device manufacture, UKAS accreditation, MHRA oversight and, for products placed in the EU, the in vitro diagnostic regulation. You do not need to memorise it all in month one. You do need to respect it.

Learn how change control works. Learn what triggers a corrective and preventive action and why the investigation matters more than the paperwork. Understand that a signature on a batch record is a legal statement. Once you internalise that discipline, it stops feeling like a constraint and starts feeling like a safety net — for patients, for your employer and for you.

Making the first year count

The transition is easier if you treat it as a deliberate re-skilling rather than a loss of freedom. Read your company's quality manual. Sit in on a customer call, even if you say nothing. Ask a regulatory colleague to walk you through a submission. Volunteer to present at a project review, and learn to say "here is what we know, here is what we do not, here is what I recommend."

Your scientific judgement remains the foundation. What changes is the scaffolding around it — planning discipline, commercial context, teamwork and documentation. Get those right, and the bench skills you spent years building finally get somewhere useful.